Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Ocugen, Inc.
  6. News
  7. Summary
    OCGN   US67577C1053

OCUGEN, INC.

(OCGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ocugen : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating

06/11/2021 | 12:10pm EDT


© MT Newswires 2021
All news about OCUGEN, INC.
08:34aOCUGEN INC : . to present pre-clinical data for OCU410 at 2nd Annual Dry AMD Therapeutic D..
AQ
10/16OCUGEN INC : . Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
10/15INSIDER SELL : Ocugen
MT
10/15OCUGEN : Thinking about buying stock in Plug Power, Cemtrex, Ocugen, NRX Pharmaceuticals, ..
PR
10/14SOCIAL BUZZ : Ocugen, AMC, BlackBerry Top WallstreetBets Stock Gainers at Thursday Close
MT
10/14SOCIAL BUZZ : BlackBerry Seeing Late Day Strength
MT
10/13SOCIAL BUZZ : Plug Power Surges, Ocugen Slides
MT
10/12CLOSE UPDATE : US Stocks Waver Ahead of Earnings, FOMC Minutes; Investors Remain Cautious ..
MT
10/12SOCIAL BUZZ : Wallstreetbets Top Stocks Ocugen, SoFi, Tesla Gain as Broader Market Slides
MT
10/12SOCIAL BUZZ : Ocugen Bulls Pushing Shares to Fresh Highs Late
MT
More news
Analyst Recommendations on OCUGEN, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -55,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -29,1x
Yield 2021 -
Capitalization 1 656 M 1 656 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 9,16x
Nbr of Employees 15
Free-Float 97,5%
Chart OCUGEN, INC.
Duration : Period :
Ocugen, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OCUGEN, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 8,33 $
Average target price 8,88 $
Spread / Average Target 6,54%
EPS Revisions
Managers and Directors
Shankar Musunuri Chairman & Chief Executive Officer
Sanjay Subramanian CFO, Secretary & Head-Corporate Development
Arun Upadhyay Vice President-Research & Development
Bruce D. Forrest Chief Medical Officer
Uday B. Kompella Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OCUGEN, INC.355.19%1 642
MODERNA, INC.220.51%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.67%47 608
SEAGEN INC.-1.81%31 287
CELLTRION, INC.-39.28%24 952